- Kit Component:
- Toxoplasma gondii:
1. Toxoplasma gondii Antigen Grade II Catalog #: OPMA04845; 1 vial = 0.2ml
2. Toxoplasma gondii Antigen Grade III Catalog #: OPMA04846; 1 vial = 0.2ml
Rubella virus Antigen Grade IV: Catalog # OPMA04524; 1 vial = 0.2ml
CMV IgM Concentrate Antigen: Catalog #: OPMA04847; 1 vial = 0.2ml
HSV‐1 Antigen: Catalog # OPMA04527; 1 vial = 0.4ml
HSV‐2 Antigen: Catalog # OPMA045216; 1 vial = 0.4ml
HSV‐1 gG Antigen: Catalog # OPMA04777; 1 vial = 0.2ml
HSV‐2 gG Antigen: Catalog # OPMA04778; 1 vial = 0.2ml
- Printable datasheet/reference manual for TORCH Antigen Sample Kit (OKMA00002)OKMA00002
- Reconstitution and Storage:
- Ship in dry ice, Store at ≤‐65C
- Target Reference:
- Centers for Disease Control and Prevention (2013):
Parasites ‐ Toxoplasmosis (Toxoplasma infection). Retrieved from : http://www.cdc.gov/parasites/toxoplasmosis/disease.html Cytomegalovirus (CMV) and Congenital CMV Infection.
Retrieved from: http://www.cdc.gov/cmv/testing‐diagnosis.html
Nahmias, AJ, Walls KW, Stewart JA, et al. The ToRCH complex‐perinatal infections associated with toxoplasma and rubella, cytomegalo‐ and herpes simplex viruses. Pediatr Res. 1971;5:405‐406
- TORCH is an acronym for a group of infections that can cause significant birth defects and even fetal death.
Other: syphilis, hepatitis B, Coxsackie virus, Epstein-Barr virus (EBV), human parvovirus, and varicella zoster
Herpes simplex virus (HSV)
Between 2‐3% of all congenital anomalies are attributed to perinatal infections, of which the TORCH agents are the most common cause of infection. The TORCH organisms typically are asymptomatic or cause only mild infections in the mother; however, there are much more serious consequences for infection to the fetus. In addition, TORCH infections pose a greater risk to the fetus and neonate if the mother is actively infected during pregnancy. Primary infections (newly acquired during pregnancy) are generally more damaging than secondary or reactivated infections. For example in the case of Rubella, infection to the mother during the first 12 weeks of gestation leads to congenital rubella syndrome in 80% of fetus and poor outcome; however, congenital infection during the second half of pregnancy has minimal risk to the fetus. For T. gondii., although the risk of maternal transmission is lowest in the first trimester, congenital disease is the most severe during this phase and often results in fetal death. CMV,
which is the most common cause of congenital infectious disease, has a much higher rate of transmission (10% vs. 1%) for mothers with a primary infection compared to a reactivation.
For most TORCH organisms, the initial screening test is based on detection of antibodies to the organism. Assays are commercially available for the detection of IgG antibodies, IgM antibodies, or both IgG and IgM antibodies. In most cases, IgG reactivity in the absence of IgM reactivity is indicative of a past infection, while IgM reactivity in the absence of IgG reactivity indicates a current infection. However, for toxoplasmosis and CMV infections, IgG avidity has recently been found to be useful for identifying primary infections. Since IgM antibodies can be produced following reactivation or re‐ infection in some individuals, a positive IgM is not necessarily indicative of a primary, active infection. In addition, it has been demonstrated that IgG antibody produced in the first few months following an initial infection has a lower avidity than IgG antibody produced several months or years later; consequently, low‐avidity antibody can be used to specifically identify high‐risk mothers with a primary infection. Overall to protect a fetus from TORCH infection, early diagnosis through first trimester screening is critical. Most TORCH infections are asymptomatic for the mother but can lead to serious birth defects or death for the fetus if left untreated.
- Mix-n-StainTM R-PE Antibody Compatibility and Labeling Protocol Selection Guide
Component Compatibility Sodium Azide Compatible, proceed to Section B Glycerol Perform ultrafiltration (Section A) Tris Compatible, proceed to Section B Glycine Compatible, proceed to Section B BSA or gelatin Up to 4X IgG (ug amount): Compatible, proceed to Section B
More than 4X IgG (ug amount): Not compatible, purify IgG
Ascites fluid Not compatible, purify IgG Serum Not compatible, purify IgG Hybridoma supernatant Not compatible: purify IgG
- Tips Information: